Dr Reddy's receives approval from Brazilian regulator to sell Ozempic generic
Read more
Business Standard
business-standard.com

Dr Reddy's receives approval from Brazilian regulator to sell Ozempic generic

The Indian pharmaceutical company Dr Reddy's Laboratories announced on Thursday that it has received authorization from Brazilian regulatory bodies to bring to market and sell the generic version of Novo Nordisk's best-selling diabetes treatment, Ozempic.

According to Dr Reddy's, there are 16.6 million adults aged 20 to 79 suffering from diabetes in Brazil, and the country ranks sixth globally in terms of such patients.

The country's National Health Surveillance Agency (ANVISA) authorized the semaglutide generic for the therapy of adults with inadequately controlled type 2 diabetes, provided they adhere to diet and exercise.

Previously, the regulatory body had rejected the drug application in April because it did not meet all established requirements.

This drug, which is taken once a week, will be available in 2 mg and 4 mg doses in a pre-filled injection pen.

Dr Reddy's was counting on semaglutide generics—the active component of Ozempic and the weight-loss drug Wegovy—as a key growth driver in both the Indian market and several global markets.

Earlier this year, the company recalled batches of the semaglutide generic in Canada after detecting an impurity in the active ingredient. Sales of this drug are planned to resume in Canada this quarter, along with entry into Latin American and African markets in the coming months.

Similar stories

FDA approves generic version of lenacapavir, monthly injection against HIV
Read more
super.abril.com.br

FDA approves generic version of lenacapavir, monthly injection against HIV

The Food and Drug Administration (FDA), the US regulatory body, granted provisional approval to the first generic version of lenacapavir. This medication is an injection administered semi-annually and offers near-complete protection against HIV infection.

The generic, produced by the Indian pharmaceutical company Dr. Reddy’s Laboratories, cannot be marketed in the US due to patent protection of the original drug. However, it can be acquired by the American government for PEPFAR, a program aimed at combating HIV abroad.

Both Dr. Reddy’s and Unitaid, a global health initiative that supported the development of the generic, aim to ensure this medication reaches low- and middle-income nations.

Dr. Reddy’s is one of six pharmaceutical companies authorized by Gilead Sciences, the creator of lenacapavir, to produce the lower-cost version. In 2024, licenses were issued to companies located in Asia and North Africa. Currently, only Dr. Reddy’s has FDA approval, but all six can distribute the medicine in 120 countries after obtaining the necessary permits. This list includes areas with high HIV rates, such as South Africa, Lesotho, Botswana, and Zimbabwe.

The annual cost of Dr. Reddy’s generic will be 40 dollars per patient. This price was established in 2025 through an agreement signed with three health entities: Unitaid, the Clinton Health Access Initiative (CHAI), and the South African institute Wits RHI. The first doses are expected to reach the countries by the end of 2026, with supply expansion anticipated in 2027.

Lenacapavir, which is injectable and applied twice a year, may represent a more effective alternative for HIV pre-exposure prophylaxis (PrEP) compared to daily pills, whose effectiveness depends on constant adherence.

The substance had already been marketed by Gilead since 2022 for HIV treatment. In 2025, it was approved in the US for prevention purposes, following clinical trials that demonstrated nearly 100% protection. In one of these studies, none of the treated women contracted the infection, and in another, only two of the 2,179 participants who used lenacapavir contracted the virus.

In 2024, Science magazine named lenacapavir the 'Advance of the Year,' recognizing the fundamental research that underpinned the drug. However, the high cost in the US, reaching about 28 thousand dollars annually, posed a major obstacle to its widespread availability.

According to Unitaid, even before the arrival of the generic, more than 125,000 individuals in ten African countries were already using Gilead-manufactured lenacapavir on an early basis. The organization emphasizes that the generic obtained 'provisional approval' from the FDA, which is the standard status for generics while the original product remains under protection.

Amazon launches installment system without card in Brazil, with up to 12 installments option
Read more
tecnoblog.net

Amazon launches installment system without card in Brazil, with up to 12 installments option

Amazon announced to Tecnoblog that it has started offering a new installment system that does not require a card directly within its application. With this, the e-commerce platform aligns itself with rivals such as Mercado Livre and Shopee, which already provide a financing option for purchases without depending on a credit or debit card.

This new feature is in the implementation phase and may not be accessible to all users. The feature, called Amazon Credit, is displayed on both the Amazon website and app, and only account holders can request it after undergoing a credit assessment.

The documentation provided by Amazon mentions the incidence of fees and interest, but the financial details are revealed only to the end consumer. It is important to clarify that this system does not constitute a loan, but rather a balance intended for the installment payment of acquisitions.

Amazon informed that the introduction of this modality will occur gradually, advising interested parties to periodically check the availability of the option. Amazon Credit serves as an alternative to traditional purchases made with a credit card, aiming to expand purchasing possibilities, following the model adopted by competitors such as Shopee, which has SParcelado.

The credit limit and the number of installments granted vary according to each customer, and not everyone will initially receive the benefit of 12 installments. This condition may change depending on usage history and timely payment compliance.

Tecnoblog investigated that the operation of Amazon Credit is not conducted directly by Amazon. In fact, the consumer formalizes the financial agreement with Celcoin Sociedade de Crédito Direto, an entity registered under CNPJ 48.632.754/0001-90, which has authorization from the Central Bank.

There are basic criteria for those who wish to obtain Amazon Credit. According to the company, it is mandatory to be between 21 and 75 years old, have a minimum monthly income of R$1,500, and present valid documentation, in addition to residing in Brazil. All customers who have an active account on Amazon can apply for Amazon Credit, but prior approval through a credit analysis is essential.

After approval, the credit system appears on Amazon. It cannot be used for loans or for purchases on external platforms. Once activated, one simply selects this option during the payment process.

Popular